Selected publications to 3D microtumor technology

 SLAS Discov. 2020 Mar;25(3):265-276

A 3D Heterotypic Multicellular Tumor Spheroid Assay Platform to Discriminate Drug Effects on Stroma versus Cancer Cells.

Weydert Z, Lal-Nag M, Mathews-Greiner L, Thiel C, Cordes H, Küpfer L, Guye P, Kelm JM, Ferrer M.

Drug Discovery Today 2019 Jan;24(1):26-30
Translational in vitro research: integrating 3D drug discovery and development processes into the drug development pipeline.
Kelm JM, Lal-Nag M, Sittampalam GS, Ferrer M.
Cancer Immunol Immunother. 2017 Jan;66(1):129-140.
A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents.
Herter S, Morra L, Schlenker R, Sulcova J, Fahrni L, Waldhauer I, Lehmann S, Reisländer T, Agarkova I, Kelm JM, Klein C, Umana P, Bacac M.
Kelm et. al., Biotechnology and Bioengineering, 2003
Biotechnol Bioeng. 2003 Jul 20;83(2)
Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety of cell types.
Kelm JM, Timmins NE, Brown CJ, Fussenegger M, Nielsen LK.

Relevant publications about functional drug profiling

Nature Medicine 2017 Sep 8;23(9):1028-1035.
Functional precision cancer medicine-moving beyond pure genomics.
Letai A.

Lancet Haematol. 2017 Dec;4(12):e595-e606.
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies.
Berend Snijder et. al.

References on molecular guided precision medicine

 Cancer Discov. 2017 Aug;7(8):818-831.
AACR Project GENIE: Powering Precision Medicine through an International Consortium.
AACR Project GENIE Consortium.

Lancet Oncol. 2015 Oct;16(13):1324-34.
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA).
Christophe Le Tourneau et. al.

JAMA Oncology 2018 Aug 1;4(8):1093-1098
Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology.
Marquart J, Chen EY, Prasad V
JAMA Netw Open. 2019 May 3;2(5)
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
Haslam A, Prasad V